Effect of roxallistat assisted erythropoietin on renal anemia patients and its effect on transferrin and transferrin saturation
Objective To investigate the effect of roxallistat assisted erythropoietin(EPO)on patients with renal anemia(RA)and its effect on transferrin(TRF)and TRF saturation(TSAT)levels.Methods A total of 179 RA patients treated in the department of nephrology,Mingguang people's hospital from January 2021 to December 2023 were selected and divided into experimental group(n=90,EPO+roxallistat)and control group(n=89,EPO)by random number table method.Both groups were treated for 12 months.The clinical efficacy,TRF,TSAT,serum indexes of anemia[red blood cell(RBC),hemoglobin(Hb),serum ferritin(SF)]and the incidence of adverse reactions were compared between the two groups.Results After treatment,the clinical effective rate of experimental group was higher than that of control group(91.11％vs 79.78％,P＜0.05).The levels of TRF,TSAT,RBC,Hb and SF in both groups were higher than before(P＜0.05),and the experimental group was higher than the control group(P＜0.05).The incidence of adverse reactions in experimental group and control group was 6.67％and 10.11％,respectively,with no significant difference(P＞0.05).Conclusion Roxallistat assisted EPO in the treatment of RA is effective,and can improve the level of TRF,TSAT and anemia.
NETL
NSTL
万方数据
